Found 16 results
Filters: Author is J.Y. Wang  [Clear All Filters]
Y. Han, Li, Q., Xu, B. H., Zhang, P., Yuan, P., Wang, J. Y., Ma, F., Cai, R. G., and Fan, Y., Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes, vol. 14, pp. 8563-8573, 2015.
J. Y. Wang, Wang, A. L., Han, W., and Mu, Z. L., Association between a functional single nucleotide polymorphism in the brain-derived neurotrophic factor gene and risk of child asthma, vol. 14, pp. 16233-16240, 2015.
J. Yao, Li, Z. H., Li, Y. X., Zhang, R., Zhang, D. G., Xu, Z. L., Wang, L. S., and Wang, J. Y., Association between the -607 C > A polymorphism in interleukin-18 gene promoter with gastrointestinal cancer risk: a meta-analysis, vol. 14, pp. 16880-16887, 2015.
G. X. Zhang, Fan, Q. C., Zhang, T., Wang, J. Y., Wang, W. H., Xue, Q., and Wang, Y. J., Genome-wide association study of growth traits in the Jinghai Yellow chicken, vol. 14, pp. 15331-15338, 2015.
T. Zhang, Fan, Q. C., Wang, J. Y., Zhang, G. X., Gu, Y. P., and Tang, Y., Genome-wide association study of meat quality traits in chicken, vol. 14, pp. 10452-10460, 2015.
T. Zhang, Zhang, G. X., Han, K. P., Tang, Y., Wang, J. Y., Fan, Q. C., Chen, X. S., Wei, Y., and Wang, Y. J., Molecular cloning and characterization, and prokaryotic expression of the GnRH1 gene obtained from Jinghai yellow chicken, vol. 14, pp. 2831-2849, 2015.
Z. Q. Du and Wang, J. Y., A novel lumazine synthase molecule from Brucella significantly promotes the immune-stimulation effects of antigenic protein, vol. 14, pp. 13084-13095, 2015.
M. A. Abdalhag, Zhang, T., Fan, Q. C., Zhang, X. Q., Zhang, G. X., Wang, J. Y., Wei, Y., and Wang, Y. J., Single nucleotide polymorphisms associated with growth traits in Jinghai yellow chickens, vol. 14, pp. 16169-16177, 2015.
X. Cui, Liu, F., Wang, J. Q., Zhang, W. J., Wang, J. Y., Liu, K., Cui, S. Y., Zhang, J., and Xu, R. R., Complete sequence analysis of mitochondrial DNA of aplastic anemia patients, vol. 11, pp. 2130-2137, 2012.
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, et al. (1999). Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat. Genet. 23: 147. PMid:10508508   Bohr VA, Stevnsner T and de Souza-Pinto NC (2002). Mitochondrial DNA repair of oxidative damage in mammalian cells. Gene 286: 127-134.   Chen D, Cao G, Hastings T, Feng Y, et al. (2002). Age-dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria. J. Neurochem. 81: 1273-1284. PMid:12068075   Chinnery PF and Schon EA (2003). Mitochondria. J. Neurol. Neurosurg. Psychiatr. 74: 1188-1199. PMid:12933917 PMCid:1738655   Clayton DA (1984). Transcription of the mammalian mitochondrial genome. Annu. Rev. Biochem. 53: 573-594. PMid:6383200   DiMauro S and Schon EA (2003). Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348: 2656-2668. PMid:12826641   Gattermann N (2000). From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk. Res. 24: 141-151.   Gattermann N (2004). Mitochondrial DNA mutations in the hematopoietic system. Leukemia 18: 18-22. PMid:14614516   Grist SA, Lu XJ and Morley AA (2004). Mitochondrial mutations in acute leukaemia. Leukemia 18: 1313-1316. PMid:15129223   Hatfill SJ, La Cock CJ, Laubscher R, Downing TG, et al. (1993). A role for mitochondrial DNA in the pathogenesis of radiation-induced myelodysplasia and secondary leukemia. Leuk. Res. 17: 907-913.   Lee MS and Levin BC (2002). MitoAnalyzer, a computer program and interactive web site to determine the effects of single nucleotide polymorphisms and mutations in human mitochondrial DNA. Mitochondrion 1: 321-326.   Linnartz B, Anglmayer R and Zanssen S (2004). Comprehensive scanning of somatic mitochondrial DNA alterations in acute leukemia developing from myelodysplastic syndromes. Cancer Res. 64: 1966-1971. PMid:15026331   Penta JS, Johnson FM, Wachsman JT and Copeland WC (2001). Mitochondrial DNA in human malignancy. Mutat. Res. 488: 119-133.   Richter C, Park JW and Ames BN (1988). Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U. S. A. 85: 6465-6467. PMid:3413108 PMCid:281993   Shadel GS and Clayton DA (1997). Mitochondrial DNA maintenance in vertebrates. Annu. Rev. Biochem. 66: 409-435. PMid:9242913   Shin MG, Kajigaya S, Levin BC and Young NS (2003). Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 101: 3118-3125. PMid:12446454   Suganuma K, Miwa H, Imai N, Shikami M, et al. (2010). Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation. Leuk. Lymphoma 51: 2112-2119. PMid:20860495   Wulfert M, Kupper AC, Tapprich C, Bottomley SS, et al. (2008). Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp. Hematol. 36: 577-586. PMid:18439489
M. Y. Huang, Chen, M. J., Tsai, H. L., Kuo, C. H., Ma, C. J., Hou, M. F., Chuang, S. C., Lin, S. R., and Wang, J. Y., Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens, vol. 10, pp. 3002-3012, 2011.
Arnold D, Hohler T, Dittrich C, Lordick F, et al. (2008). Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann. Oncol. 19: 1442-1449. PMid:18441330 Bleiberg H (1996). Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol. 23: 42-50. Cunningham D, Humblet Y, Siena S, Khayat D, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337-345. PMid:15269313 Department of Health, Executive Yuan (2007). Statistics on Leading Causes of Cancer Death. Bureau of National Health Insurance, Taiwan. Fakih M (2008). The role of targeted therapy in the treatment of advanced colorectal cancer. Curr. Treat. Options Oncol. 9: 357-374. PMid:19238551 Fang JY and Richardson BC (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6: 322-327. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17: 450-456. PMid:16303861 Giacchetti S, Perpoint B, Zidani R, Le Bail N, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18: 136-147. PMid:10623704 Giovanella BC, Stehlin JS, Wall ME, Wani MC, et al. (1989). DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048. PMid:2555920 Hemming AW, Davis NL, Kluftinger A, Robinson B, et al. (1992). Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51: 147-152. PMid:1434639 Kallen KJ, Hofmann MA, Timm A, Godderz W, et al. (2000). Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z. Gastroenterol. 38: 153-157. PMid:10721170 Lenz HJ, Van Cutsen E, Khambata-Ford S, Mayer RJ, et al. (2006). Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24: 4914-4921. PMid:17050875 Lievre A, Bachet JB, Boige V, Cayre A, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26: 374-379. PMid:18202412 Liu LF, Desai SD, Li TK, Mao Y, et al. (2000). Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922: 1-10. PMid:17132771 Loe DW, Deeley RG and Cole SP (1996). Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A: 945-957. Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, et al. (2001). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 37: 1000-1005. Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, et al. (2008). Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br. J. Cancer 99: 455-458. PMid:18665167    PMCid:2527794 Midgley RS, Yanagisawa Y and Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 108-120. Min BS, Kim NK, Ahn JB, Roh JK et al. (2007). Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30: 637-643. PMid:18063876 Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, et al. (2007). Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46: 697-701. PMid:17562448 Recchia F, Candeloro G, Necozione S, Bratta M, et al. (2008). Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 31: 323-328. PMid:18845989 Reidy D and Saltz L (2007). Targeted strategies in the treatment of metastatic colon cancer. J. Natl. Compr. Canc. Netw. 5: 983-990. PMid:17977504 Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, et al. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22: 1201-1208. PMid:14993230 Sambrook J, Jritsch E and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, et al. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25: 5225-5232. PMid:18024868 Teufel A, Steinmann S, Siebler J, Zanke C, et al. (2004). Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4: 38. PMid:15265233    PMCid:497044 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216. PMid:10655437 van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, et al. (1998). Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J. Cancer 77: 2171-2176. PMid:9649129    PMCid:2150393 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360: 1408-1417. PMid:19339720 Wang JY, Hsieh JS, Chen FM, Yeh CS, et al. (2003). High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int. J. Cancer 107: 387-393. PMid:14506738 Yen LC, Uen YH, Wu DC, Lu CY, et al. (2010). Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann. Surg. 251: 254-260. PMid:20010090